Brandon A Mahal1, Gino Inverso2, Ayal A Aizer3, R Bruce Donoff4, Sung-Kiang Chuang5. 1. Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA. 2. Harvard School of Dental Medicine, 188 Longwood Ave., Boston, MA 02115, USA. 3. Harvard Radiation Oncology Program, Massachusetts General Hospital, 55 FruitStreet, Boston, MA 02114, USA. 4. Harvard School of Dental Medicine, 188 Longwood Ave., Boston, MA 02115, USA; Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. 5. Harvard School of Dental Medicine, 188 Longwood Ave., Boston, MA 02115, USA; Department of Oral and Maxillofacial Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: sung-kiang_chuang@hms.harvard.edu.
Abstract
OBJECTIVES: To determine the associations between African American race and stage at diagnosis, receipt of definitive therapy, and cancer-specific mortality among patients with head and neck cancer. MATERIALS AND METHODS: The Surveillance, Epidemiology and End Results (SEER) database was used to conduct a retrospective study on 34,437 patients diagnosed with head and neck cancer from 2007 to 2010. Multivariable logistic regression analyses were applied to determine the impact of race on cancer stage at presentation (metastatic vs. non-metastatic) and receipt of definitive treatment. Fine and Gray competing-risks regression modeled the association between race and head and neck cancer-specific mortality. RESULTS: African Americans were more likely to present with metastatic cancer compared to non-African Americans (Adjusted Odds Ratio [AOR] 1.76; CI 1.50-2.07; P<0.001). Among patients with non-metastatic disease, African Americans were less likely to receive definitive treatment (AOR 0.63; CI 0.55-0.72; P<0.001). After a median follow-up of 19months, African Americans with non-metastatic disease were found to have a higher risk of head and neck cancer specific mortality (AHR 1.19; 95% CI 1.09-1.29; P<0.001). CONCLUSION: African Americans with head and neck cancer are more likely to present with metastatic disease, less likely to be treated definitively, and are more likely to die from head and neck cancer. The unacceptably high rates of disparity found in this study should serve as immediate targets for urgent healthcare policy intervention.
OBJECTIVES: To determine the associations between African American race and stage at diagnosis, receipt of definitive therapy, and cancer-specific mortality among patients with head and neck cancer. MATERIALS AND METHODS: The Surveillance, Epidemiology and End Results (SEER) database was used to conduct a retrospective study on 34,437 patients diagnosed with head and neck cancer from 2007 to 2010. Multivariable logistic regression analyses were applied to determine the impact of race on cancer stage at presentation (metastatic vs. non-metastatic) and receipt of definitive treatment. Fine and Gray competing-risks regression modeled the association between race and head and neck cancer-specific mortality. RESULTS: African Americans were more likely to present with metastatic cancer compared to non-African Americans (Adjusted Odds Ratio [AOR] 1.76; CI 1.50-2.07; P<0.001). Among patients with non-metastatic disease, African Americans were less likely to receive definitive treatment (AOR 0.63; CI 0.55-0.72; P<0.001). After a median follow-up of 19months, African Americans with non-metastatic disease were found to have a higher risk of head and neck cancer specific mortality (AHR 1.19; 95% CI 1.09-1.29; P<0.001). CONCLUSION: African Americans with head and neck cancer are more likely to present with metastatic disease, less likely to be treated definitively, and are more likely to die from head and neck cancer. The unacceptably high rates of disparity found in this study should serve as immediate targets for urgent healthcare policy intervention.
Authors: Carol M Lewis; Gaurav S Ajmani; Alexandra Kyrillos; Paul Chamberlain; Chi-Hsiung Wang; Cheryl C Nocon; Monica Peek; Mihir K Bhayani Journal: Head Neck Date: 2018-06-26 Impact factor: 3.147
Authors: Luke R G Pike; Trevor J Royce; Amandeep R Mahal; Daniel W Kim; William L Hwang; Brandon A Mahal; Nina N Sanford Journal: J Natl Compr Canc Netw Date: 2020-02 Impact factor: 11.908
Authors: Nicholas R Lenze; Douglas Farquhar; Siddharth Sheth; Jose P Zevallos; Jeffrey Blumberg; Catherine Lumley; Samip Patel; Trevor Hackman; Mark C Weissler; Wendell G Yarbrough; Adam M Zanation; Andrew F Olshan Journal: Laryngoscope Date: 2020-11-10 Impact factor: 3.325
Authors: Marc A Emerson; Douglas R Farquhar; Nicholas R Lenze; Siddharth Sheth; Angela L Mazul; Adam M Zanation; Trevor G Hackman; Mark C Weissler; Jose P Zevallos; Wendell G Yarbrough; Paul Brennan; Behnoush Abedi-Ardekani; Andrew F Olshan Journal: Head Neck Date: 2022-01-19 Impact factor: 3.147
Authors: Siddharth Sheth; Douglas R Farquhar; Nicholas R Lenze; Angela Mazul; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Jose P Zevallos; D Neil Hayes; F Olshan Journal: Am J Otolaryngol Date: 2020-10-22 Impact factor: 1.808
Authors: Michael M Li; Songzhu Zhao; Antoine Eskander; Chandler Rygalski; Guy Brock; Anuraag S Parikh; Catherine T Haring; Brian Swendseid; Kevin Y Zhan; Carol R Bradford; Theodoros N Teknos; Ricardo L Carrau; Kyle K VanKoevering; Nolan B Seim; Matthew O Old; James W Rocco; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2021-07-15 Impact factor: 4.339